Why the study?
Data regarding the risk of permanent pacemaker implantation requirement in patients with preexisting right bundle branch block undergoing TAVR was scarce.
Does preexisting RBBB increase the risk of permanent pacemaker implantation and all-cause mortality in patients undergoing TAVR?
Does preexisting RBBB increase the risk of permanent pacemaker implantation and all-cause mortality in patients undergoing TAVR?
Preexisting RBBB in patients undergoing TAVR is a strong predictor for requiring a permanent pacemaker and is associated with higher 30-day all-cause mortality.
Preexisting RBBB signals higher PPI risk after TAVR; extends observational data but leaves open need for prospective validation before practice change.
Introduction . Transcatheter aortic valve replacement (TAVR) is now the treatment of choice for patients with severe aortic stenosis regardless of their surgical risk. Right bundle branch block (RBBB) can be a predictor for development of significant atrioventricular (AV) block after TAVR, requiring permanent pacemaker implantation (PPI). However, data related to the risk of PPI requirement with preexisting RBBB is scarce. Hence, this systematic review and meta-analysis aims to assess clinical outcomes of patients undergoing TAVR with RBBB on preexisting electrocardiogram. Methods . We performed a systematic literature review to identify randomized and nonrandomized clinical studies that reported any clinical impact of patients undergoing TAVR with preexisting RBBB. A total of eight databases including PubMed (Medline), Embase, Cochrane Library, ACP Journal Club, Scopus, DARE, and Ovid containing articles from January 2000 to May 2020 were analyzed. Results . We identified and screened 224 potential eligible publications through the databases and found 14 relevant clinical trials for a total of 15,319 participants. There was an increased 30-day pacemaker implantation rate of 38.1% in the RBBB group compared to 11.4% in the no RBBB group with a risk ratio of 3.56 (RR 3.56 (95% CI 3.21–3.93, p<0.01)). There was an increased 30-day all-cause mortality in the RBBB group of 9.5% compared with 6.3% in the no RBBB group with an odds ratio of 1.60 (OR 1.60 (95% CI 1.14–2.25, p<0.01)). Conclusion . This study indicates that patients with preexisting RBBB have higher incidence of PPI and all-cause mortality after TAVR compared with patients without RBBB. Further trials are needed to compare the clinical outcomes based on TAVR valve types and assess the benefit of PPI in patients with new-onset RBBB after TAVR.
No takes yet. Share an insight, caveat, or question.
Croix et al. (2020) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: